In women with locally advanced HER2+ breast cancer who have had a complete response to neoadjuvant chemotherapy, what factors impact your decision to offer PMRT?

Does your recommendation change for women with HER2- disease?

Community PollStarted

Would you omit PMRT in HER2+ patients with pCR?

289 physicians have voted

Join Mednetto vote and see how they answered.

2 Answers

Mednet MemberInvited Expert

Radiation Oncology · Varian Medical Systems/Allegheny health network

Answered on

Currently, the use of PMRT should be based on pre treatment staging. If pretreatment staging is stage III, I would recommend RT. If pretreatment nodal staging is IIB would favor observation but would also consider for B51 study randomizing between RT vs observation.

Join for free or sign in to see the full answer

Mednet Member

Radiation Oncology · Vanderbilt-Ingram Cancer Center

Answered on

For my practice, any node positive patients (even T2N1) eligible for B51 would be offered enrollment. Off-protocol I would treat.

Any patient with up-front cT4 or cN2+ disease (not eligible for B51) gets PMRT.

cT3N0 prior to chemotherapy would be an individualized discussion with the patient but wou...

Join for free or sign in to see the full answer